Representative Investments

C2Sense uses nanotechnology to develop miniaturized mobile sensing solutions for a healthier and safer world. Rapid medical diagnostics, product authentication, environmental monitoring and building/worker safety are just some of the key areas that C2Sense serves. 

Fluorityx is an MIT spin-out with cutting-edge PFAS water detection technology that provides low-cost, on-site, rapid testing at performance levels 100X more sensitive than the next-best device in the market.

Intermodal Transfer Terminal on Ohio River with a dock and railroad spur facilities.

Intervala is a full-service manufacturer of high-reliability, precision electronic and electromechanical products for companies in industrial, medical, transportation, and other technology-driven markets.

Liquid X Printed Metals, Inc., a Carnegie Mellon University spin-out, is an advanced material manufacturer of functional metallic inks that takes an application from prototype to production.

Longevity Health Holdings is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics.

MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection.

Plano has been a supplier to outdoor enthusiasts of equipment protection and storage solutions such as fishing tackle boxes and gun cases for over 60 years. The company was sold in 2012.

PredxBio, a University of Pittsburgh spin-out, identifies response-defining tissue patterns across spatial multi-omic data, enabling earlier go/no-go decisions, stronger biomarker strategies, and more efficient clinical development.

Sharp Therapeutics, a Carnegie Mellon University spin-out, is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases.

Xibus, an MIT spin-out, is a food and beverage safety company that is developing a microbiological testing solution applicable to pathogens, allergens and spoilage organisms. Merged into Fluorityx in 2025.